Hangzhou Sino-American Huadong Pharmaceutical Jiangdong

Hangzhou Sino-American Huadong Pharmaceutical Jiangdong is a major manufacturing and industrialization subsidiary of Huadong Medicine, located in the Qiantang District of Hangzhou, China. The facility serves as a cornerstone of the parent company's production strategy, focusing on high-value therapeutics in metabolic diseases, immunology, and oncology. It possesses extensive capabilities in large-scale fermentation, chemical synthesis, and the production of active pharmaceutical ingredients (APIs) and finished dosage forms. The Jiangdong site is instrumental in the commercialization of Huadong's GLP-1 receptor agonist portfolio, including liraglutide and semaglutide biosimilars, and supports a robust pipeline of innovative biologics. Adhering to international quality standards, the company plays a vital role in Huadong Medicine's transition into an innovation-driven global pharmaceutical player.